NCT01962246View on ClinicalTrials.gov

Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

169

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

February 29, 2020

Study Completion Date

August 31, 2021

Conditions
Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Oxaliplatin; Capecitabine

Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for eight cycles postoperation

OTHER

Oxaliplatin; Capecitabine; concurrent radiotherapy

Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for two cycles preoperation , Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation Radiation: radiotherapy 50 Gy in 25 fractions (2Gy /day, 5 days/week,Monday through Friday, ) Other Name: XRT

Trial Locations (1)

050011

Department of General Surgery, Shijiazhuang

All Listed Sponsors
lead

Hebei Medical University

OTHER

NCT01962246 - Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction | Biotech Hunter | Biotech Hunter